DOCSLIB.ORG

Patient-Controlled Transdermal Fentanyl Hydrochloride Vs Intravenous Morphine Pump for Postoperative Pain a Randomized Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient-Controlled Transdermal Fentanyl Hydrochloride Vs Intravenous Morphine Pump for Postoperative Pain a Randomized Controlled Trial ORIGINAL CONTRIBUTION Patient-Controlled Transdermal Fentanyl Hydrochloride vs Intravenous Morphine Pump for Postoperative Pain A Randomized Controlled Trial Eugene R. Viscusi, MD Context Patient-controlled analgesia (PCA) with morphine is commonly used to pro- Lowell Reynolds, MD vide acute postoperative pain control after major surgery. The fentanyl hydrochloride Frances Chung, MD patient-controlled transdermal system eliminates the need for venous access and com- plicated programming of pumps. Linda E. Atkinson, PhD Objective To assess the efficacy and safety of an investigational patient-controlled Sarita Khanna, PhD iontophoretic transdermal system using fentanyl hydrochloride compared with a stan- dard intravenous morphine patient-controlled pump. ATIENT-CONTROLLED ANALGE- Design, Setting, and Patients Prospective randomized controlled parallel-group sia (PCA) allows the patient to trial conducted between September 2000 and March 2001 at 33 North American hos- self-administer small doses of pitals, enrolling 636 adult patients who had just undergone major surgery. opioids, such as fentanyl, mor- Interventions In surgical recovery rooms, patients were randomly assigned to in- Pphine, hydromorphone, or meperi- travenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient- dine, as needed to manage pain. A key controlled analgesia pump (n=320) or iontophoretic fentanyl hydrochloride (40-µg principle of PCA use is that it is initi- infusion over 10 minutes) by a patient-controlled transdermal system (n=316). Supple- ated after titration to patient comfort mental analgesia (morphine or fentanyl intravenous boluses) was administered as needed with loading doses of intravenous (IV) before and for the first 3 hours after activation of the PCA treatments. Patients then opioids.1 Thereafter, PCA is used to used the PCA treatments without additional analgesics for up to 72 hours. maintain a mild level of pain rather than Main Outcome Measures The primary efficacy variable was patient global as- total pain relief, allowing the patient to sessment of the method of pain control during the first 24 hours. Additional efficacy self-administer enough drug to achieve measures were the proportion of patients discontinuing the study because of inad- equate analgesia for any reason, patient-reported pain intensity scores on a 100-mm a comfortable balance between analge- 2-5 visual analog scale (VAS), and patient global assessments at 48 and 72 hours. Adverse sia and adverse effects. Existing PCA effects were also recorded. therapies infuse opioid analgesics Results Ratings of good or excellent after 24 hours of treatment for the method of through an IV line at a preset rate by pain control were given by 73.7% of patients (233/316) who used transdermal fen- electronic pumps or by disposable, tanyl PCA and 76.9% of patients (246/320) who used intravenous morphine PCA; fixed-volume devices when a patient ac- treatment difference was –3.2% (95% confidence interval, –9.9% to 3.5%; P=.36). tivates a dosing button. Problems that Early patient discontinuations (25.9% fentanyl vs 25.0% morphine; P=.78) and last compromise patient safety, such as pro- pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P=.45) were not gramming errors, uncontrolled deliv- different between the 2 treatments. With continued treatment for up to 48 or 72 ery of syringe contents, and patient tam- hours, more than 80% of patient assessments in each treatment group were good or pering, have been reported.6 Pump excellent. The incidence of opioid-related adverse events was similar between the failures and syringe mix-ups are also groups. possible. Conclusion An investigational PCA transdermal system using iontophoresis to de- To overcome these problems, a fen- liver fentanyl provided postsurgical pain control equivalent to that of a standard in- tanyl hydrochloride patient-con- travenous morphine regimen delivered by a PCA pump. trolled transdermal system (PCTS) is JAMA. 2004;291:1333-1341 www.jama.com under development as an alternative Author Affiliations and Financial Disclosures are listed Department of Anesthesiology, Thomas Jefferson Uni- method that delivers small doses of fen- at the end of this article. versity, 111 S 11th St, Suite G 8490, Philadelphia, PA tanyl by iontophoresis with electro- Corresponding Author: Eugene R. Viscusi, MD, 19107 ([email protected]). ©2004 American Medical Association. All rights reserved. (Reprinted) JAMA, March 17, 2004—Vol 291, No. 11 1333 Downloaded From: https://jamanetwork.com/ on 10/01/2021 PATIENT-CONTROLLED POSTOPERATIVE ANALGESIA: PATCH VS PUMP transport delivery platform technol- tion was developed to eliminate any bias a subsequent 5-minute lockout and a ogy (E-TRANS; ALZA Corp, Mountain on the part of the investigators and their limit of 10 doses per hour (10 mg). The View, Calif). The system uses a low- staff and to balance the number of pa- choice of the active comparator regi- intensity direct current to move fen- tients between the 2 treatments and the men is supported by the research of tanyl from a hydrogel reservoir into the surgery types. Eligible patients were as- Owen and colleagues,9 who showed an skin, where it then diffuses into the lo- signed a study treatment (fentanyl PCTS optimal balance between efficacy and cal circulation and is transported to the or IV PCA morphine) with an interac- adverse effects at an on-demand mor- central nervous system. The self- tive voice response system randomiza- phine dose of 1 mg compared with on- adhesive unit, about the size of a credit tion procedure.8 The investigators and demand doses of 0.5 and 2 mg and us- card, is worn on the patient’s upper arm their staff did not know the block size ing a dosing interval of 5 minutes. or chest, does not have the IV tubing, or the next treatment assignment be- Ginsberg et al10 demonstrated similar cables, and large pump of the IV PCA, fore randomization. efficacy for PCA regimens incorporat- and may facilitate patient mobility. The ing various lockout periods from 2 to opioid analgesic fentanyl has a poten- Patient-Controlled 8 minutes. Because of the confound- tial advantage over morphine in that it Transdermal System ing logistics—patients would have does not have active metabolites that The fentanyl hydrochloride PCTS is to press 2 dosing buttons simulta- can accumulate over time.7 manufactured to function within pre- neously—the study was not blinded, For these advantages to be realized, set dosing specifications. It operates for which would have required an IV PCA the delivery method must provide pain 24 hours after the first dose is deliv- pump and a fentanyl PCTS for each control that is comparable to that of cur- ered or delivers a maximum of 80 doses patient. rent standard therapy. The purpose of and shuts off. The dose, controlled by this study was to establish that the trans- the amount of electrical current, is fixed Patients dermal PCA delivery system is equiva- to not exceed 40 µg, the dosing inter- Names of prospective participants were lent to a standard morphine IV PCA regi- val is 10 minutes, and each dose is a 10- selected from hospital surgical sched- men in postoperative pain management. minute infusion. Drug delivery begins ules. The patients were approached by when the electrical current is acti- anesthesiologists or surgeons to ascer- METHODS vated by pressing the dosing button tain interest in joining the study. Pa- Study Design twice within 3 seconds. During deliv- tients (N=726) were screened within A prospective, randomized, parallel- ery of the dose, the fentanyl PCTS can- 2 weeks before enrollment, written in- group, unblinded, active-controlled not deliver additional doses, and de- formed consent was obtained, and study was conducted from September livery of the dose cannot be interrupted medical history and a physical exami- 2000 to March 2001 at 29 US and 4 Ca- or extended. nation were conducted. Patients were nadian hospitals. Centers were re- The system provides an audible instructed in the use of the fentanyl cruited according to the knowledge of (beep) and visual indication (red light PCTS and IV PCA morphine pump and postoperative pain management of the from a light-emitting diode) that a dose in the performance of the study assess- local investigator and the proven abil- has begun. The light turns off momen- ments. Patients were aged at least 18 ity of staff to conduct research. The in- tarily when the dose has been com- years; were American Society of Anes- stitutional review board, research eth- pleted and then flashes to indicate the thesiologists physical status I, II, or III ics board, or an independent centralized approximate number of doses deliv- (no, mild to moderate, or severe sys- ethics review board approved the pro- ered. One flash represents delivery of temic disturbance, respectively); were tocol. Patients provided signed in- 1 to 5 doses, 2 flashes represent deliv- scheduled to undergo general or re- formed consent during the screening ery of 6 to 10 doses, and so on. Be- gional anesthesia for major abdomi- process. cause the maximum number of doses nal, orthopedic, or thoracic surgery; and allowed by the system is 80, the corre- were expected to have moderate or se- Randomization sponding maximum number of flashes vere pain requiring parenteral opioids A randomization schedule was cre- is 16. Alerts for nonfunctioning con- for at least 24 hours after surgery. ated with computer-generated ran- ditions are a short series of beeps (the Postoperative screening occurred dom numbers in a block size of 4 by us- fentanyl PCTS should be restarted) and when patients were admitted to the ing all patients, regardless of center. The continuous beeping (the system has postanesthesia care unit (PACU; recov- patients were stratified by type of sur- shut down and should be removed).
Load more

Recommended publications
  • Effect of Intranasal Ketamine Vs Fentanyl on Pain
    1 PROTOCOL SYNOPSIS 2 STUDY TITLE: 3 Pain Reduction with Intranasal Medications for Extremity Injuries (PRIME): A Randomized Clinical 4 Noninferiority Trial of Intranasal Ketamine vs. Fentanyl 5 6 PROTOCOL TITLE 7 Pain Reduction with Intranasal Medications for Extremity injuries (PRIME) 8 9 PRINCIPAL INVESTIGATOR: 10 Theresa M. Frey, MD 11 Assistant Professor Clinical Pediatrics 12 Division of Pediatric Emergency Medicine 13 Cincinnati Children’s Hospital Medical Center 14 513-636-7966 15 [email protected] 16 17 CO-INVESTIGATORS: 18 Matthew R. Mittiga, MD 19 Todd A. Florin, MD, MSCE 20 Michelle C. Caruso, PharmD, BCPS 21 Nanhua Zhang, PhD 22 Yin Zhang, MS 23 24 I. ABSTRACT 25 26 Introduction: Inadequate pain control in the emergency department, particularly in the pediatric 27 population, is a major health concern. The intranasal route of medication administration is gaining 28 popularity secondary to its rapid onset of action, minimal discomfort for the patient and relative 29 simplicity. When pediatric patients present with moderate to severe pain from traumatic injuries, 30 opioids are currently the most frequently used class of analgesia, but they may not always be the best 31 option for numerous reasons. Sub-dissociative dosing of ketamine has been shown to be an effective 32 alternative to opioids in providing adequate pain relief. 33 34 Objectives: The objectives of this study are to 1) determine if intranasal ketamine is non-inferior to 35 intranasal fentanyl in reduction of pain in children presenting with extremity injuries and 2) define and 36 compare the level of sedation and respiratory side effect profile associated with intranasal ketamine and 37 fentanyl.
    [Show full text]
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Fentanyl Infographic 24X36
    FENTANYL WHAT IS IT? Fentanyl can be found in prescription form, introduced to the medical community in the 1960s Fentanyl analogues are now being Fentanyl is a potent synthetic and prescribed to relieve severe pain post-surgery created in clandestine laboratories to opioid analgesic, 50 to 100x or during end-of-life care . In its prescription form, be sold and used illegally. In it's non- more powerful than fentanyl is sold under the brand names Actiq®, prescription form, fentanyl is found in morphine. Duragesic®, and Sublimaze®. When prescribed by a powder form, spiked on blotter paper; physician, fentanyl is often administered via mixed with heroin; or as tablets that injection, transdermal patch, or in lozenges. attempt to mimic other opioids. Effects: Like other opioids, Fentanyl binds to Through Fentanyl's effects on the Euphoria, relaxation, drowsiness, opioid receptors in the reward centers opioid receptors in the brain stem nausea, confusion, constipation, of the brain, increasing dopamine however, it can inhibit normal sedation, tolerance, addiction, levels to cause a surge in endorphins breathing, causing breathing to stop respiratory depression and arrest, and feelings of pleasure. altogether, leading to death. unconsciousness, coma, and death. WHY DOES IT MATTER? 540% While the fast-acting nature of the effects of fentanyl may create a more powerful and immediate euphoria, these increase in fentanyl effects wear off faster, leading to the more immediate return overdose deaths of cravings and discomfort. since 2016 (CDC) With a high profit margin, Fentanyl is often mixed into heroin or is made to mimic the In talking about Fentanyl, you may hear about appearance of other opioids.
    [Show full text]
  • Marijuana Is Cannabis with Tetrahydrocannabinol (THC). Strains Without THC Are Often Classified As Hemp
    “COMBATING 21ST CENTURY DRUGS WITH SUCCESSFUL OUTCOMES” William L. Parker CEO American Court & Drug Testing Services [email protected] THE SUPREME COURT OF OHIO SPECIALIZED DOCKETS CONFERENCE Fentanyl and its correlation to fatal overdoses Thursday, October 11, 2018 in Ohio, a relatively new threat called Flakka, 11:45 a.m. – 1:00 p.m. CBD oils and how to incorporate these drugs into an effective drug testing program. Friday, October 12, 2018 1:15 p.m. – 2:30 p.m. FENTANYL Fentanyl is an opioid which is used as a pain medication and together with other medications for anesthesia or to relieve pain in terminally ill cancer patients. Fentanyl is available in a number of forms including by injection, as a skin patch, and to be absorbed through the tissues inside the mouth. Fentanyl about 75 times stronger than morphine for a given amount. Some fentanyl analogues may be as much as 10,000 times stronger than morphine. FENTANYL Fentanyl was created in 1959 by Paul Jannsen, founder of Jannsen Pharmaceutical and first used medically as anesthetic in 1968. Fentanyl patches were first introduced in the mid 1990’s as a pain management treatment for Opiate-tolerate patients. Fentanyl was first used for pain management in cancer patients in 2009. FENTANYL Recreational use of Fentanyl started in the mid 1970’s among medical professionals. The use of Fentanyl – especially from the illegal manufacturing of the drug has increased exponentially over the past three years. Since 2012 Fentanyl related overdoses and deaths have produced staggering statistics in almost every state in the U.S.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • Post- Operative Pain- Relief
    PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff • Pain is often the patient’s presenting symptom. It can provide useful clinical information and it is your responsibility to use this information to help the patient and alleviate suffering. • Manage pain wherever you see patients (emergency, operating room and on the ward) and anticipate their needs for pain management after surgery and discharge. • Do not unnecessarily delay the treatment of pain; for example, do not transport a patient without analgesia simply so that the next practitioner can appreciate how much pain the person is experiencing. • Pain management is our job. Pain Management and Techniques • Effective analgesia is an essential part of postoperative management. • Important injectable drugs for pain are the opiate analgesics. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac (1 mg/kg) and ibuprofen can also be given orally and rectally, as can paracetamol (15 mg/kg). • There are three situations where an opiate might be given: pre- operatively, intra-operatively, post-operatively. •• Opiate premedication is rarely indicated, although an injured patient in pain may have been given an opiate before coming to the operating room. • Opiates given pre- or intraoperatively have important effects in the postoperative period since there may be delayed recovery and respiratory depression, even necessitating mechanical ventilation. (continued to next page) PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff ((ccoonnttiiinnuueedd)) • Short acting opiate fentanyl is used intra-operatively to avoid this prolonged effect. • Naloxone antagonizes (reverses) all opiates, but its effect quickly wears off. • Commonly available inexpensive opiates are pethidine and morphine. • Morphine has about ten times the potency and a longer duration of action than pethidine.
    [Show full text]
  • Do You Know... Methadone
    Do You Know... Street names: juice, meth (also used to refer to methamphetamines) What is it? Methadone belongs to the opioid family of Methadone drugs. It is used most commonly to treat addiction to other opioid drugs such as heroin, oxycodone (e.g., Percodan, Percocet), fentanyl (e.g., Duragesic, Sublimaze) and hydromorphone (e.g., Dilaudid). Methadone is a synthetic opioid, which means that it is made from chemicals in a lab. Methadone was developed in Germany during the Second World War and was first used to provide pain relief. Methadone maintenance treatment, which prevents opioid withdrawal and reduces or eliminates drug cravings, was first developed in the 1960s. For many years, Canadian reg- ulations around the prescription of methadone were so restrictive that few doctors offered the treatment. People who wanted methadone treatment often had to wait months or years. 1/4 © 2003, 2011, 2012 CAMH | www.camh.ca In the 1990s, the need to reduce the harm of drug use with medical care, improves the chances of having a was more clearly recognized, and changes were made healthy baby. There are no known long-term effects of to make it easier for doctors to provide methadone methadone on the baby. treatment. People who inject opioid drugs regularly, and who are Methadone maintenance is not a “cure”: it is a treatment. HIV- or hepatitis C–positive, are enrolled in methadone Through treatment, people who are addicted to opioids treatment to help protect their health. Methadone receive the medical and social support they need to treatment also helps to prevent these infections from stabilize and improve their lives.
    [Show full text]
  • Pain Management
    PAIN MANAGEMENT GENERAL CONSIDERATIONS A. Pain management in the pre-hospital setting should be limited to patients with moderate to severe pain. The EMT must always consider the type of pain, the patient’s overall condition, allergies, co-existing medical conditions, and drug contraindications when deciding if pain management is appropriate and which pain medication should be administered. B. Evaluate and document the following: • Vital signs • Level of consciousness • Patient’s description of pain • Location of pain • Severity (see diagrams below) • Does pain radiate? • Is it reproducible? • Associated symptoms? (Nausea, vomiting, diaphoresis, lightheadedness, etc.) • If pain medications administered, assess and document the effects of the medication. Pain Scale 0 1 2 3 4 5 6 7 8 9 10 No Pain Horrible Distress Dreadful Annoying Agonizing Unbearable No Distress Uncomfortable Pediatric Patients – The Wong-Baker FACES Pain Rating Scale 0 2 4 6 8 10 Effective 2/1/19 Pain Management Page 1 of 4 Replaces 11/1/14 C. The EMT must be prepared for potential complications of pain medications. 1. If patient becomes hypotensive administer IV normal saline fluid bolus: • 250 – 500 ml for adult patient • 20 ml/kg for pediatric patient (to a maximum of 500ml) • Repeat boluses as needed to maintain BP 2. If LOC decreases and/or respiratory depression occur, manage airway appropriately. 3. Consider Narcan administration if respiratory depression does not quickly resolve or if patient is over-sedated. 4. Giving medications slowly will help you avoid complications. For all mediations below, “slow push” means administration of the drug over 1-2 minutes Guidelines as to which medication is most appropriate for specific situations are outlined below.
    [Show full text]
  • Rubiscolins Are Naturally Occurring G Protein-Biased Delta Opioid Receptor Peptides
    European Neuropsychopharmacology (2019) 29, 450–456 www.elsevier.com/locate/euroneuro SHORT COMMUNICATION Rubiscolins are naturally occurring G protein-biased delta opioid receptor peptides a , 1 a, 1 a Robert J. Cassell , Kendall L. Mores , Breanna L. Zerfas , a a, b , c a ,b , c Amr H. Mahmoud , Markus A. Lill , Darci J. Trader , a, b ,c , ∗ Richard M. van Rijn a Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA b Purdue Institute for Drug Discovery, West Lafayette, IN 47907, USA c Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907, USA Received 6 August 2018; received in revised form 19 November 2018; accepted 16 December 2018 KEYWORDS Abstract Delta opioid receptor; The impact that β-arrestin proteins have on G protein-coupled receptor trafficking, signaling Beta-arrestin; and physiological behavior has gained much appreciation over the past decade. A number of Natural products; studies have attributed the side effects associated with the use of naturally occurring and syn- Biased signaling; thetic opioids, such as respiratory depression and constipation, to excessive recruitment of Rubisco; β-arrestin. These findings have led to the development of biased opioid small molecule ago- G protein-coupled nists that do not recruit β-arrestin, activating only the canonical G protein pathway. Similar G receptor protein-biased small molecule opioids have been found to occur in nature, particularly within kratom, and opioids within salvia have served as a template for the synthesis of other G protein- biased opioids. Here, we present the first report of naturally occurring peptides that selectively activate G protein signaling pathways at δ opioid receptors, but with minimal β-arrestin recruit- ment.
    [Show full text]
  • Levorphanol Use: Past, Present and Future
    Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Levorphanol Use: Past, Present and Future Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu To cite this article: Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu (2015): Levorphanol Use: Past, Present and Future, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1128308 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1128308 Accepted author version posted online: 03 Dec 2015. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [Jeffrey Fudin] Date: 03 December 2015, At: 20:32 Publisher: Taylor & Francis Journal: Postgraduate Medicine DOI: 10.1080/00325481.2016.1128308 Levorphanol Use: Past, Present and Future Authors: Jeffrey Gudin1, Jeffrey Fudin2, and Srinivas Nalamachu3 Affiliations: 1Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center, Englewood, NJ, and Clinical Instructor, Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. 2Adjunct Associate Professor, Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy Director, PGY2 Pain Residency and Clinical Pharmacy, Specialist, Pain Management Stratton VA Medical Center, Albany, NY 3President and Medical Director, International Clinical Research Institute, Overland Park, KS, and Adjunct Associate Professor, Temple University School of Medicine, Downloaded by [Jeffrey Fudin] at 20:32 03 December 2015 Philadelphia, PA. Running Title: Levorphanol Use: Past, Present and Future Corresponding Author Srinivas Nalamachu Srinivas R. Nalamachu MD International Clinical Research Institute, Inc.
    [Show full text]